KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$187.5 million.

  • Novavax's Income from Continuing Operations fell 66.84% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 219.97%. This contributed to the annual value of -$187.5 million for FY2024, which is 65.60% up from last year.
  • Latest data reveals that Novavax reported Income from Continuing Operations of -$187.5 million as of FY2024, which was up 65.60% from -$545.1 million recorded in FY2023.
  • Novavax's 5-year Income from Continuing Operations high stood at -$187.5 million for FY2024, and its period low was -$1.7 billion during FY2021.
  • Its 3-year average for Income from Continuing Operations is -$463.5 million, with a median of -$545.1 million in 2023.
  • Per our database at Business Quant, Novavax's Income from Continuing Operations slumped by 316.91% in 2021 and then skyrocketed by 65.60% in 2024.
  • Novavax's Income from Continuing Operations (Yearly) stood at -$418.3 million in 2020, then plummeted by 316.91% to -$1.7 billion in 2021, then soared by 62.27% to -$657.9 million in 2022, then grew by 17.16% to -$545.1 million in 2023, then skyrocketed by 65.60% to -$187.5 million in 2024.